A deeper understanding of the proteomic profiles of disease is crucial for future research efforts, and cohorts focused on cardiovascular phenotypes are among the largest to leverage these platforms thus far (2,9,13,33). Proteomic insights can improve disease prediction, uncover novel pathways, and identify drug targets (2,22,34). Compared to previous proteomic platform comparisons, which were limited by sample size (16), a key strength of our **data** is that they provide a more comprehensive investigation across multiple domains for two of the most widely used profiling platforms available within two large, well-phenotyped cohorts. Using these data, researchers may be better equipped to interpret existing proteomic **data** and/or plan future investigations with a clearer understanding of the relative strengths and limitations of each platform.